Selected studies of intensive therapy with BCR-ABL1 TKIs for Ph+ ALL
| Study . | Regimen . | N . | Age, median (range), y . | CR rate, % . | IM, % . | Overall survival . |
|---|---|---|---|---|---|---|
| UKALLXII/E299335 | Imatinib + chemotherapy | 175 | 42 (16-64) | 92 | 5 | 38% (4 y) |
| MDACC36 | Imatinib + HyperCVAD | 70 | 51 (17-84) | 93 | 2 | 43% (5 y) |
| MDACC40 | Dasatinib + HyperCVAD | 72 | 55 (21-80) | 96 | 4 | 52% (5 y) |
| Korean28 | Nilotinib + multiagent chemotherapy | 90 | 47 (17-77) | 91 | 9 | 72% (2 y) |
| MDACC44 | Ponatinib + HyperCVAD | 86 | 46 (21-80) | 100 | 0 | 78% (3 y) |
| PONAFIL56 | Ponatinib + chemotherapy | 30 | 49 (19-59) | 100 | 0 | 96% (3 y) |
| Study . | Regimen . | N . | Age, median (range), y . | CR rate, % . | IM, % . | Overall survival . |
|---|---|---|---|---|---|---|
| UKALLXII/E299335 | Imatinib + chemotherapy | 175 | 42 (16-64) | 92 | 5 | 38% (4 y) |
| MDACC36 | Imatinib + HyperCVAD | 70 | 51 (17-84) | 93 | 2 | 43% (5 y) |
| MDACC40 | Dasatinib + HyperCVAD | 72 | 55 (21-80) | 96 | 4 | 52% (5 y) |
| Korean28 | Nilotinib + multiagent chemotherapy | 90 | 47 (17-77) | 91 | 9 | 72% (2 y) |
| MDACC44 | Ponatinib + HyperCVAD | 86 | 46 (21-80) | 100 | 0 | 78% (3 y) |
| PONAFIL56 | Ponatinib + chemotherapy | 30 | 49 (19-59) | 100 | 0 | 96% (3 y) |
IM, induction mortality; MDACC, MD Anderson Cancer Center.